The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design

Amanj Baker, Li-Chia Chen, Rachel A. Elliott, Brian Godman

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)
81 Downloads (Pure)


In April/2009, the UK National Health Service initiated four Better Care Better Value (BCBV) prescribing indicators, one of which encouraged the prescribing of cheaper angiotensin-converting enzyme inhibitors (ACEIs) instead of expensive angiotensin receptor blockers (ARBs), with 80 % ACEIs/20 % ARBs as a proposed, and achievable target. The policy was intended to save costs without affecting patient outcomes. However, little is known about the actual impact of the BCBV indicator on ACEIs/ARBs utilisation and cost-savings. Therefore, this study aimed to evaluate the impact of BCBV policy on ACEIs/ARBs utilisation and cost-savings, including exploration of regional variations of the policy’s impact.
Original languageEnglish
Article number367
Number of pages15
JournalBMC Health Services Research
Publication statusPublished - 10 Sep 2015


  • better care better value
  • angiotensin-converting enzyme inhibitors
  • angiotensin receptor blockers
  • cardiovascular disease
  • hypertension
  • pharmacoeconomics

Cite this